Taysha rais­es $150M PIPE, shares sin­gle pa­tient da­ta on Rett syn­drome gene ther­a­py

Taysha Gene Ther­a­pies an­nounced it raised $150 mil­lion from a stock sale to in­vestors as it un­veiled da­ta from a sin­gle Rett syn­drome pa­tient who re­ceived its gene ther­a­py.

The da­ta are still ear­ly and very lim­it­ed, but in a sin­gle adult fe­male pa­tient who re­ceived its Rett syn­drome gene ther­a­py, Taysha said there have been no safe­ty is­sues at six weeks. On one pri­ma­ry end­point, Taysha said the clin­i­cian re­port­ed a score of two on a sev­en-point im­prove­ment scale, mean­ing the pa­tient was “much im­proved” at four weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER